Actively Recruiting
Evaluating BCMACD19 Dual Targeted CAR-T Cell Therapy for Adults with Relapsed or Refractory Autoimmune Kidney Diseases
Led by Nanjing University School of Medicine · Updated on 2026-07-06
24
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effects of BCMACD19 dual targeted CAR-T cell therapy FKC289 in adults with relapsed or refractory autoimmune kidney diseases including lupus nephritis, ANCA-associated vasculitis, membranous nephropathy, and IgG4-related diseases. This phase 1, open-label, dose-escalation study plans to enroll 6 to 12 participants using a Bayesian Optimal Interval design with four dose groups ranging from 0.1 to 3.0 x 106 CAR T cellskg. Participants undergo leukapheresis to collect cells for manufacturing the CAR-T therapy. Before infusion, they receive lymphodepletion with fludarabine and cyclophosphamide over three days. After a one-day rest, participants receive a single intravenous infusion of the assigned dose of BCMACD19 dual targeted CAR-T cells. Bridging therapy is permitted between cell collection and lymphodepletion. Following infusion, participants are followed for at least two years. During the study, participants are monitored for dose-limiting toxicities within 28 days and adverse events within 24 weeks after infusion. Researchers also measure renal response within 6 months and track duration of response, progression-free survival, and overall survival over 2 years. Assessments include clinical evaluations and laboratory tests to ensure safety and evaluate treatment effects over the study period.
CONDITIONS
Brief Title
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
Research Team
X
Xianghua Huang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here